Engitix Therapeutics to Relocate Headquarters to New Life Sciences Cluster, White City Place

Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based on its proprietary human extracellular matrix (ECM) platform, today announced that it is relocating its headquarters and operations to WestWorks, White City Place (WCP).
The move follows announcements of high-profile collaboration agreements with Takeda Pharmaceuticals and Morphic Therapeutic, to leverage the benefits of Engitix’ human ECM-based discovery platform to improve the success rate of drug discovery and development.
This acknowledgement from two major players in the industry underpins the Company’s expansion, which starts with it moving to the 8,000 square feet facility of bespoke office and laboratory space in WCP.

Related Keywords

United Kingdom ,London ,City Of , ,Digestive Health ,University College London ,Institute For Liver ,Novartis ,Takeda Pharmaceuticals ,Division Of Medicine ,Engitix Ltd ,White City Place ,Morphic Therapeutic ,Gammadelta Therapeutics ,White City ,Engitix Therapeutics ,ஒன்றுபட்டது கிஂக்டம் ,லண்டன் ,நகரம் ஆஃப் ,செரிமான ஆரோக்கியம் ,பல்கலைக்கழகம் கல்லூரி லண்டன் ,நிறுவனம் க்கு கல்லீரல் ,நோவர்த்திச் ,டாகேடா மருந்துகள் ,பிரிவு ஆஃப் மருந்து ,வெள்ளை நகரம் இடம் ,மார்பிக் சிகிச்சை ,வெள்ளை நகரம் ,